AZ starts next-gen ADC dev with confidence from Enhertu

By | translator Alice Kang

22.04.04 06:16:21

가나다라 0

Phase III trial on datopotamab started in Korea and abroad… targets triple-negative breast cancer

Signs agreement for 2 ADCs with Daiichi Sankyo worth 15 trillion won

Also plans to reveal its next-gen ADC that applied their own linker technology

AstraZeneca is leading the next-generation ADC development environment. The company, which has successfully commercialized ‘Enhertu’ in partnership with Daiichi Sankyo, is targeting areas slow in development such as triple-negative breast cancer.

On the 31st, AstraZeneca received approval for its Phase III trial of a new ADC drug last month. The new ADC drug subject to the trial is ‘datopotamab deruxtecan (DS-1062, hereafter datopotamab),’ a TROP2 targeting ADC that is being co-developed by AstraZeneca and Daiichi Sankyo.

The Phase III trial for datopotamab will be conducted on patients with unresectable locally advanced or metastatic triple-negative breast cancer. The trial will e

(same@dailypharm.com)

If you want to see the full article, please JOIN US (click)